#San Diego #Avidity Biosciences #Novartis AG #RNA

Avidity Biosciences Announces Special Meeting Update

Avidity Biosciences, Inc. (NASDAQ: RNA), a pioneering biopharmaceutical company focused on innovating RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), has recently made headlines with its decision to postpone a special meeting of its stockholders, originally set for February 23, 2026. The company will immediately adjourn the meeting without addressing further business matters, aiming to reconvene on February 26, 2026.

The primary reason for this adjournment is to provide Avidity with additional time to finalize the conditions necessary for the pro rata distribution of Atrium Therapeutics, Inc. common stock (referred to as SpinCo) to its stockholders. This distribution is crucial for the success of Avidity’s proposed merger with Novartis AG, thus prompting the need for the delay.

In this context, Avidity has indicated that the anticipated share distribution will occur on February 26, 2026, while the merger is expected to close shortly afterwards on February 27, 2026. However, both the distribution and the merger completion depend on satisfying certain closing conditions outlined in Avidity's Definitive Proxy Statement filed on January 30, 2026. Stockholder approval is paramount in these proceedings.

For those already registered for the original special meeting, they will not need to re-register to attend the reconvened session, which will be accessible via the same virtual link provided: www.proxydocs.com/RNA. Furthermore, stockholders who have already cast their votes through proxy submissions will see their votes counted at the reconvened session unless they decide to revoke them.

Avidity expressed its commitment to facilitating the transition of its stock symbol as part of the merger's finalization. For a limited time, Avidity's shares will trade under the symbol